Lupin inks pact for acquisition of brands ‘Ondero' and ‘Ondero — Met'

25 Aug 2022 , 09:25 AM

Lupin Limited announced that the company has entered into a Deed of Assignment with Boehringer Ingelheim International GmbH for the acquisition of brands Ondero and Ondero – Met (including trademark rights associated with the brands), which will enable the Company to provide comprehensive and best-in-class treatment options for diabetes management.

The brands are associated with diabetes medications. Lupin’s diabetes portfolio is likely to generate value.

The said acquisition is for a cash consideration of Euro 26 million (Rs207.26 crore approx.).

Boehringer Ingelheim International GmbH is a business formed under German law. It is engaged in the pharmaceutical sector.

At around 9.28 AM, Lupin was trading at Rs677.70 up by 0.01% from its previous closing of Rs677.65 on the BSE. The scrip opened at Rs675.70 and touched intraday high and low of Rs680.35 and Rs673.70 respectively.

For feedback and suggestions, write to us at [e-mail]